Overview of cardiovascular physiologic and pharmacologic aspects of selective phosphodiesterase peak III inhibitors
- 3 January 1989
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 63 (2) , A9-A11
- https://doi.org/10.1016/0002-9149(89)90385-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicineThe American Journal of Cardiology, 1989
- Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesteraseThe American Journal of Cardiology, 1989
- Role of cyclic AMP in regulating cardiac muscle contractility: Novel pharmacological approaches to modulating cyclic AMP degradation by phosphodiesteraseDrug Development Research, 1988
- Effect of Milrinone (Corotrope) on the Contractility of Isolated Dog Ventricular MuscleJournal of Cardiovascular Pharmacology, 1987
- Modulation of cAMPJournal of Cardiovascular Pharmacology, 1986
- Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failureThe American Journal of Cardiology, 1986
- Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure.Circulation, 1985
- Cyclic Nucleotides and Regulation of Vascular Smooth MuscleJournal of Cardiovascular Pharmacology, 1984
- Characterization of the Cardiotonic Effects of Milrinone, a New and Potent Cardiac Bipyridine, on Isolated Tissues from Several Animal SpeciesJournal of Cardiovascular Pharmacology, 1983
- Role of cyclic nucleotides in heart metabolismCardiovascular Research, 1982